TwentyTwentyTweetsTweets by 2020health
Join 7,195 other subscribers
Category Archives: Drugs
Are pharmaceutical mega-mergers in the public interest?
The main reason for governments around the world to encourage the pharmaceutical industry is to support Research and Development – R&D – with a view to the discovery of new drugs of future benefit to mankind. Commercial pharmaceutical companies have played … Continue reading
Posted in Business, competition, Drugs, Innovation, International, Pharma, Policy, Research, Technology Tagged 2020health, AstraZeneca, Beecham, Boots, competition, David Jack, Drugs, Glaxo, innovation, Keith Mansford, medicine, merger, Pfizer, pharmaceutical, R&D, Research, Sir David Jack, SmithKline, Smithkline Beecham, Tagamet, takeover Leave a comment
Medical advisory body “NICE” should not spend too much time valuing drugs.
The UK National Institute for Health and Care Excellence (“NICE”) is currently holding a public consultation over its proposals for evaluating drugs. Drugs that are approved by NICE automatically become available for doctors to prescribe under the NHS throughout England … Continue reading
Posted in Business, CCGs, Commissioning, Department of Health, Drugs, Elderly, equality, Genetics, GPs, Health and Wellbeing, Health Bill, Health reform, Inequality, Innovation, Jeremy Hunt, NHS, NHS reforms, Patients, Pharma, Policy, Public Health, Research, Technology, Uncategorized, Wellbeing Tagged 2020health, Clinical Commissioning Group, Commissioning, Department of Health, dose, elderly, General practitioner, government, GP, GPs, health, Health Bill, innovation, Jeremy Hunt, medicine, Medicines and Healthcare products Regulatory Agency, MHRA, National Health Service, National Institute for Health and Care Excellence, NHS, NICE, Old age, patient, Patients, pharmaceutical, PPRS, pricing, Proportionate QALY, Public Health, QALY, R&D, Research, value-based, value-based pricing Leave a comment
Legal High Lies
It was terribly sad listening to the bother of a “legal high” victim on the radio this morning. The now banned N-Bomb LSD copycat drug had left his brother severely brain damaged and dependent on 24 hour care for the … Continue reading
Posted in Drugs Tagged addiction, death, Drugs, Legal highs, psychoactive substances Leave a comment
Guest Blogspot: Negotiations with the UK Government over pharmaceutical pricing have achieved a good result for patients, the NHS and the industry.
The UK Government and the pharmaceutical industry shared many objectives throughout the recent drug pricing negotiations. For example, there was always broad agreement that: The total future drug bill needed to be affordable in the context of other spending in … Continue reading
Posted in Andrew Lansley, Business, Cancer, Department of Health, Drugs, Innovation, Jeremy Hunt, NHS, Patients, Pharma, Research, Smoking ban Tagged 2020health, Andrew Lansley, Department of Health, Drugs, government, innovation, Jeremy Hunt, National Health Service, NHS, NICE, parallel export, parallel imporrt, patient, Patient Access Scheme, Patients, pharmaceutical, PPRS, pricing, R&D, Research, value-based, value-based pricing, VBP 1 Comment
Is “listening” the key to reducing antibiotic prescribing?
Wednesday will see the publication of a report on GPs over-prescribing antibiotics for patients – nothing new there – but this has a twist: GPs over-prescribing antibiotics even when the patients are not particularly asking for them. This comes at … Continue reading
Pharmaceutical companies must be free to determine their own research priorities: Lessons from Alzheimer’s Disease
Guest blog post from Barbara Arzymanow, Independent Healthcare Consultant Sir David Jack (1924-2011), one of history’s greatest pharmaceutical R&D directors under whom many important drugs were discovered, once told me that neither governments nor companies should overrule senior R&D management. … Continue reading
Posted in Business, Drugs, Innovation Tagged acetylcholine, acetylcholinesterase, Alzheimer's, block-buster, British Biotech, C1-inh, cholinesterase, David Jack, glutamate, hub, innovation, marimastat, medicine, mental health, Neurochem, NICE, NMDA, pharmaceutical, R&D, Research, Sir David Jack Leave a comment
Guest Blogspot: Waiting for Decisions on UK Pharmaceutical Pricing
Little has been heard over how confidential talks between the Government and the pharmaceutical industry are progressing towards the goal of having a new, voluntary UK drug pricing system in place in 2014. In the eyes of the pharmaceutical companies … Continue reading
Posted in Andrew Lansley, Business, Children, Commissioning, David Cameron, Department of Health, Drugs, Emerging technologies, equality, Health and Wellbeing, Innovation, Jeremy Hunt, Uncategorized, Wellbeing Tagged 2020health, Andrew Lansley, Bowel Cancer UK, Cancer Research UK, Drugs, government, innovation, medicine, Multiple Sclerosis Society, pharmaceutical, R&D, value-based, value-based pricing 1 Comment
Access to orphan medicines: rare expertise and patient experience needs to be core part of decision
Blogpost by Leela Barham, Independent Health Economist and 2020health Research Fellow for Empower Access to Medicines Orphan medicines are used to treat some of the rarest conditions; conditions that affect less than 5 per 10,000 people in Europe. Some of … Continue reading
Guest Blogspot: Think carefully about value-based drug pricing in the UK and let common sense prevail.
David Cameron and Jeremy Hunt share an important skill. They both have firsts from Oxford in Politics, Philosophy and Economics (PPE). I am not the greatest fan of this course because I would like to see more scientists, engineers and … Continue reading
Posted in Business, competition, David Cameron, Department of Health, Drugs, Election, Jeremy Hunt, NHS, Patients, Pharma, Policy, Primary Care Tagged 2020health, block-buster, competition, David Cameron, demand, Department of Health, drug pricing system, Drugs, elderly, GP, GPs, Health Bill, innovation, medicine, National Health Service, NHS, NICE, parallel exports, parallel imports, patient, Patients, pharmaceutical, Philosophy and Economics, Politics, PPE, PPRS, pricing, quality of life, R&D, reference price, Research, value-based, value-based pricing, VBP Leave a comment
You must be logged in to post a comment.